Advances in Molecular OncologyAdvances in Molecular OncologyУспехи молекулярной онкологии2313-805X2413-3787Publishing House ABV Press35210.17650/2313-805X-2021-8-2-23-28REVIEW ARTICLESОБЗОРНЫЕ СТАТЬИPrognostic and predictive significance of osteopontin in malignant neoplasmsПрогностическая и предиктивная значимость остеопонтина при злокачественных новообразованияхhttps://orcid.org/0000-0001-7025-0206ZubarevaE. Yu.ЗубареваЕ. Ю.
Russian Federation

Evgenia Yuryevna Zubareva

11 Gagarin Avenue, Orenburg 460021, Russia

6 Sovetskaya St., 460000 Orenburg, Russia

Евгения Юрьевна Зубарева

Россия, 460021 Оренбург, пр-т Гагарина, 11

Россия, 460000 Оренбург, ул. Советская, 6

tishkova_evgeniy@mail.ruhttps://orcid.org/0000-0001-8371-740XSenchukovaM. A.СеньчуковаМ. А.
Russian Federation

11 Gagarin Avenue, Orenburg 460021, Russia

6 Sovetskaya St., 460000 Orenburg, Russia

Россия, 460021 Оренбург, пр-т Гагарина, 11

Россия, 460000 Оренбург, ул. Советская, 6

Orenburg Regional Clinical Oncological DispensaryГБУЗ «Оренбургский областной клинический онкологический диспансер»Orenburg State Medical UniversityФГБОУ ВО «Оренбургский государственный медицинский университет»150520218223282807202128072021Copyright ©; 2021, Zubareva E.Y., Senchukova M.A.Copyright ©; 2021, Зубарева Е.Ю., Сеньчукова М.А.2021Zubareva E.Y., Senchukova M.A.Зубарева Е.Ю., Сеньчукова М.А.https://creativecommons.org/licenses/by/4.0https://umo.abvpress.ru/jour/article/view/352

Osteopontin is an extracellular matrix protein which is produced by different types of cells and plays an important functional role in many biological processes. This review discusses the main functions of osteopontin, its role in the progression and chemoresistance of malignant neoplasms, in the regulation of epithelial-mesenchymal transition, angiogenesis, and the body’s immune response to the tumor. The article considers the currently known mechanisms by which osteopontin affects to the survival, mobility and invasion of tumor cells, to tumor sensitivity to drug treatment, as well as the prospects for a integrated study of the predictive significance of osteopontin, markers of hypoxia, angiogenesis, epithelial- mesenchymal transition, and immunological tolerance.

Остеопонтин – это белок внеклеточного матрикса, который продуцируется разными типами клеток и играет важную функциональную роль во многих биологических процессах. В данном обзоре рассматриваются основные функции остеопонтина, его роль в прогрессии и химиорезистентности злокачественных новообразований, регуляции эпителиально-мезенхимального перехода, ангиогенеза и иммунного ответа организма на опухоль. В статье обсуждаются известные в настоящий момент механизмы, при помощи которых остеопонтин оказывает влияние на выживаемость, подвижность и инвазию опухолевых клеток, чувствительность опухоли к лекарственному лечению, а также представлены перспективы комплексного изучения предиктивной значимости этого белка, маркеров гипоксии, ангиогенеза, эпителиально-мезенхимального перехода и иммунологической толерантности.

osteopontinprogression of malignant neoplasmsinvasionmetastasisepithelial-mesenchymal transitionimmunological tolerancehypoxiaangiogenesischemoresistanceостеопонтинпрогрессия злокачественных новообразованийинвазияметастазированиеэпителиально-мезенхимальный переходиммунологическая толерантностьгипоксияангиогенезхимиорезистентностьDenhardt D.T., Guo X. Osteopontin: a protein with diverse functions. FASEB J 1993;7(15):1475–82.Berezin A.E., Panasenko T.A., Koretskaya E.Yu. Osteopontin as a new biological marker of cardiovascular remodeling. Ukrainskij kardiologicheskij zhurnal = Ukrainian Journal of Cardiology 2010;4:98–102.(In Russ.).Березин А.Е., Панасенко Т.А., Корецкая Е.Ю. Остеопонтин как новый биологический маркер сердечно-сосудистого ремоделирования. Украинский кардиологический журнал 2010;4: 98–102.Shibanova I.A., Khryachkova O.N. The use of biomarkers of phosphoruscalcium metabolism for the diagnosis and risk stratification of patients with coronary heart disease. Russkij medicinskij zhurnal = Russian Medical Journal 2017;20:1409–14.(In Russ.).Шибанова И.А., Хрячкова О.Н. Ис- пользование биомаркеров фосфорно- кальциевого обмена для диагностики и риск-стратификации больных ишемической болезнью сердца. Русский медицинский журнал 2017;20:1409–14.Wai P.Y., Kuo P.C. The role of osteopontin in tumor metastasis. J Surg Res 2004;121(2):228–41. DOI: 10.1016/j.jss.2004.03.028.Gimba E., Brum M., Moraes G.N. Fulllength osteopontin and its splice variants as modulators of chemoresistance and radioresistance (Review). Int J Oncol 2019 Feb;54(2):420–30. DOI: 10.3892/ijo.2018.4656.Senger D.R., Wirth D.F., Hynes R.O. Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell 1979;16:885–93. DOI: 10.1016/0092-8674(79)90103-X.Kayukova E.V., Belokrinitskaya T.E., Volokhov L.F., Tereshkov P.P. The level of some hematological inflammatory markers in patients with cervical cancer, depending on the morphological features of the primary tumor. Uspekhi molekulyarnoy onkologii = Advances in Molecular Oncology 2019;6(3):49–56. (In Russ.). DOI: 10.17650/2313-805X-2019-6-3-49-56.Каюкова Е.В., Белокриницкая Т.Е., Шолохов Л.Ф., Терешков П.П. Уровень некоторых гематологических воспалительных маркеров у больных раком шейки матки в зависимости от морфологических особенностей первичной опухоли. Успехи молекулярной онкологии 2019;6(3):49–56.Moorman H.R., Poschel D., Klement J.D. et al. Osteopontin: a key regulator of tumor progression and immunomodulation. Can cers(Basel) 2020;12(11):3379. DOI: 10.3390/cancers12113379.Castello L.M., Raineri D., Salmi L. et al. Osteopontin at the crossroads of inflammation and tumor progression. Mediators Inflamm 2017;2017:4049098. DOI: 10.1155/2017/4049098.Zhou Y., Yao Y., Sheng L. et al. Osteopontin as a candidate of therapeutic application for the acute brain injury. J Cell Mol Med 2020;24(16):8918–29. DOI: 10.1111/jcmm.15641.Mirza M., Shaughnessy E., Hurley J.K. et al. Osteopontin-c is a selective marker of breast cancer. Int J Cancer 2008;122(4): 889–97. DOI: 10.1002/ijc.23204.Zduniak K., Ziolkowski P., Ahlin C. et al. Nuclear osteopontin-c is a prognostic breast cancer marker. Br J Cancer 2015; 112(4):729–38. DOI: 10.1038/bjc.2014.664.Tang X., Li J., Yu B. et al. Osteopontin splice variants differentially exert clinicopathological features and biological functions in gastric cancer. Int J Biol Sci 2013;9(1):55–66. DOI: 10.7150/ijbs.5280.Jia R., Liang Y., Chen R. et al. Osteopontin facilitates tumor metastasis by regulating epithelial-mesenchymal plasticity. Cell Death Dis 2016;7(12): e2564. DOI: 10.1038/cddis.2016.422.Irby R.B., McCarthy S.M., Yeatman T.J. Osteopontin regulates multiple functions contributing to human colon cancer development and progression. Clin Exp Metastasis 2004;21(6):515–23. DOI: 10.1007/s10585-004-2873-4.Hedley B.D., Welch D.R., Allan A.L. et al. Downregulation of osteopontin contributes to metastasis suppression by breast cancer metastasis suppressor 1. Int J Cancer 2008; 123(3):526–34. DOI: 10.1002/ijc.23542.Bandopadhyay M., Bulbule A., Butti R. et al. Osteopontin as a therapeutic target for cancer. Expert Opin Ther Targets 2014;18(8):883–95. DOI: 10.1517/14728222.2014.925447.Mohammadi S., Ghaffari S.H., Shaiegan M. et al. Acquired expression of osteopontin selectively promotes enrichment of leukemia stem cells through AKT/mTOR/PTEN/β-catenin pathways in AML cells. Life Sci 2016;152:190–8. DOI: 10.1016/j.lfs.2016.04.003.Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. J Clin Investig 2009;119(6):1420–8. DOI: 10.1172/JCI39104.Cao J., Li J., Sun L. et al. Hypoxia-driven paracrine osteopontin/integrin αvβ3 signaling promotes pancreatic cancer cell epithelial-mesenchymal transition and cancer stem cell-like properties by modulating forkhead box protein M1. Mol Oncol 2019;13(2):228–45. DOI: 10.1002/1878-0261.12399.Li N.Y., Weber C.E., Mi Z. et al. Osteopontin up-regulates critical epithelial-mesenchymal transition transcription factors to induce an aggressive breast cancer phenotype. J Am Coll Surg 2013;217(1):17–26. DOI: 10.1016/j.jamcollsurg.2013.02.025.Li N.Y., Weber C.E., Wai P.Y. et al. An MAPK-dependent pathway induces epithelial-mesenchymal transition via Twist activation in human breast cancer cell lines. Surgery 2013;154(2):404–10. DOI: 10.1016/j.surg.2013.05.012.Dong Q., Zhu X.-C., Dai C. et al. Osteopontin regulated epithelialmesenchymal transition via PI3K/AKT signaling pathway in hepatocellular carcinoma. Cancer Res 2013;73:2695. Available at: https://cancerres.aacrjournals.org/content/73/8_Supplement/2695.short.Ng L., Wan T.M.-H., Lam C.S.-Ch. et al. Post-operative plasma osteopontin predicts distant metastasis in human colorectal cancer. PLoS One 2015;10(5):e0126219. DOI: 10.1371/journal.pone.0126219.Scimeca M., Giannini E., Antonacci C. et al. Microcalcifications in breast cancer: An active phenomenon mediated by epithelial cells with mesenchymal characteristics. BMC Cancer 2014;14:286. DOI: 10.1186/1471-2407-14-286.Rizwan A., Paidi S.K., Zheng C. et al. Mapping the genetic basis of breast microcalcifications and their role in metastasis. Sci Rep 2018;8(1):11067. DOI: 10.1038/s41598-018-29330-9.Kothari A.N., Arffa M.L., Chang V. et al. Osteopontin-A master regulator of epithelial-mesenchymal transition. J Clin Med 2016 Mar 23;5(4):39. DOI: 10.3390/jcm5040039.Gnemmi V., Bouillez A., Gaudelot K. et al. MUC1 drives epithelial-mesenchymal transition in renal carcinoma through Wnt/β-catenin pathway and interaction with SNAIL promoter. Cancer Lett 2014;346(2):225–36. DOI: 10.1016/j.canlet.2013.12.029.Zhu M., Yin F., Fan X. et al. Decreased TIP30 promotes Snail-mediated epithelial–mesenchymal transition and tumor-initiating properties in hepatocellular carcinoma. Oncogene 2015;34(11): 1420–31. DOI: 10.1038/onc.2014.73.Bhattacharya S.D., Mi Z., Kim V.M. et al. Osteopontin regulates epithelial mesenchymal transition-associated growth of hepatocellular cancer in a mouse xenograft model. Ann Surg 2012;255(2):319–25. DOI: 10.1097/SLA.0b013e31823e3a1c.Song G., Cai Q., Mao Y. et al. Osteopontin promotes ovarian cancer progression and cell survival and increases HIF-1α expression through the PI3-K/Akt pathway. Cancer Sci 2008;99(10):1901–7. DOI: 10.1111/j.1349-7006.2008.00911.x.Song G., Ouyang G., Mao Y. et al. Osteopontin promotes gastric cancer metastasis by augmenting cell survival and invasion through Akt-mediated HIF-1α up-regulation and MMP9 activation. J Cell Mol Med 2009;13(8B):1706–18. DOI: 10.1111/j.1582-4934.2008.00540.x.Kothari A.N., Mi Z., Zapf M., Kuo P.C. Novel clinical therapeutics targeting the epithelial to mesenchymal transition. Clin Transl Med 2014;3:14–35. DOI: 10.1186/s40169-014-0035-0.Nakano M., Ariyama H., Tamura S. et al. Plasticity of CD44 colorectal cancer stem cells depends on TGF-beta-induced epithelial mesenchymal transition (EMT): evidences from ex vivo culture system. Cancer Res 2015;75. Available at: https://cancerres.aacrjournals.org/content/75/15_Supplement/1520.short.Pore M.M., Buikema L., Hiltermann T., Kruyt F. TGF beta-mediated epithelial to mesenchymal transition in non small cell lung cancer: Effects on stemness, invasiveness and chemotherapy sensitivity. Cancer Res 2012;72:2402. DOI: 10.1158/1538-7445.AM2012-2402.Yu Y., Xiao C., Tan L. et al. Cancerassociated fibroblasts induce epithelial– mesenchymal transition of breast cancer cells through paracrine TGF-β signalling. Br J Cancer 2014;110(3):724–32. DOI: 10.1038/bjc.2013.768.Clemente N., Raineri D., Cappellano G. et al. Osteopontin bridging innate and adaptive immunity in autoimmune diseases. J Immunol Res 2016;2016:7675437. DOI: 10.1155/2016/7675437.Shurin M.R. Osteopontin controls immunosuppression in the tumor microenvironment. J Clin Investig 2018;128(12):5209–12. DOI: 10.1172/JCI124918.Weber G.F., Zawaideh S., Hikita S. et al. Phosphorylation-dependent interaction of osteopontin with its receptors regulates macrophage migration and activation. J Leukoc Biol 2002;72(4):752–61. DOI: 10.1189/jlb.72.4.752.Klement J.D., Paschall A.V., Redd P.S. et al. An osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion. J Clin Investig 2018;128(12):5549–60. DOI: 10.1172/JCI123360.Wei J., Marisetty A., Schrand B. et al. Osteopontin mediates glioblastomaassociated macrophage infiltration and is a potential therapeutic target. J Clin Investig 2019;129(1):137–49. DOI: 10.1172/JCI121266.Fan X., He C., Jing W. et al. Intracellular osteopontin inhibits toll-like receptor signaling and impedes liver carcinogenesis. Cancer Res 2015;75(1):86–97. DOI: 10.1158/0008-5472.CAN-14-0615.Silva V.R., Neves S.P., Santos L.S. et al. Challenges and therapeutic opportunities of autophagy in cancer therapy. Cancers (Basel) 2020;12(11):3461. DOI: 10.3390/cancers12113461.Liu G., Fan X., Tang M. et al. Osteopontin induces autophagy to promote chemo-resistance in human hepatocellular carcinoma cells. Cancer Lett 2016;383(2):171–82. DOI: 10.1016/j.canlet.2016.09.033.Lei Y., Zhang D., Yu J. et al. Targeting autophagy in cancer stem cells as an anticancer therapy. Cancer Lett 2017;393:33–9. DOI: 10.1016/j.canlet.2017.02.012.Zhang H., Lu B. The roles of ceRNAsmediated autophagy in cancer chemoresistance and metastasis. Cancers (Basel) 2020;12(10):2926. DOI: 10.3390/cancers12102926.Yang M.C., Wang H.C., Hou Y.C. et al. Blockade of autophagy reduces pancreatic cancer stem cell activity and potentiates the tumoricidal effect of gemcitabine. Mol Cancer 2015;14:179. DOI: 10.1186/s12943-015-0449-3.Panah Z., Nikbakht M., Sajjadi S.M. et al. Anti-apoptotic effects of osteopontin via the up-regulation of AKT/mTOR/β- catenin loop in acute myeloid leukemia cells. Int J Hematol Oncol Stem Cell Res 2017;11(2):148–57.Ding K., Fan L., Chen S. et al. Overexpression of osteopontin promotes resistance to cisplatin treatment in HCC. Oncol Rep 2015;34(6):3297–303. DOI: 10.3892/or.2015.4306.Liu X., Fan D. The epithelial-mesenchymal transition and cancer stem cells: functional and mechanistic links. Curr Pharm Des 2015;21(10):1279–91. DOI: 10.2174/1381612821666141211115611.Pang H., Cai L., Yang Y. et al. Knockdown of osteopontin chemosensitizes MDA-MB-231 cells to cyclophosphamide by enhancing apoptosis through activating p38 MAPK pathway. Cancer Biother Radio 2011;26(2):165–73. DOI: 10.1089/cbr.2010.0838.Yang L., Wei L., Zhao W. et al. Downregulation of osteopontin expression by RNA interference affects cell proliferation and chemotherapy sensitivity of breast cancer MDA-MB-231 cells. Mol Med Rep 2012;5(2):373–6. DOI: 10.3892/mmr.2011.679.Yi H., Zeng D., Shen Z. et al. Integrin alphavbeta3 enhances β-catenin signaling in acute myeloid leukemia harboring Fmslike tyrosine kinase-3 internal tandem duplication mutations: implications for microenvironment influence on sorafenib sensitivity. Oncotarget 2016;7(26):40387–97. DOI: 10.18632/oncotarget.9617.Han B., Huang J., Han Y. et al. The microRNA miR-181c enhances chemosensitivity and reduces chemoresistance in breast cancer cells via downregulating osteopontin. Int J Biol Macromol 2019;125:544–56. DOI: 10.1016/j.ijbiomac.2018.12.075.Gu T., Ohashi R., Cui R. et al. Osteopontin is involved in the development of acquired chemo-resistance of cisplatin in small cell lung cancer. Lung Cancer 2009;66(2):176–83. DOI: 10.1016/j.lungcan.2009.02.004.Insua-Rodríguez J., Pein M., Hongu T. et al. Stress signaling in breast cancer cells induces matrix components that promote chemoresistant metastasis. EMBO Mol Med 2018;10(10):e9003. DOI: 10.15252/emmm.201809003.Ng L., Wan T., Chow A. et al. Osteopontin overexpression induced tumor progression and chemoresistance to oxaliplatin through induction of stemlike properties in human colorectal cancer. Stem Cells Int 2015;2015:247892. DOI: 10.1155/2015/247892.Pectasides D., Papaxoinis G., Kalogeras K.T. et al. XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a hellenic cooperative oncology group phase III trial with collateral biomarker analysis. BMC Cancer 2012;12:271. DOI: 10.1186/1471-2407-12-271.Thoms J.W., Dal Pra A., Anborgh P.H. et al. Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response. Br J Cancer 2012;107(5):840–6. DOI: 10.1038/bjc.2012.345.Elbaiomy M.A., Akl T., Elhelaly R. et al. Osteopontin level and promoter polymorphism in patients with metastatic breast cancer. Curr Oncol 2020;27(5): e444–e450. DOI: 10.3747/co.27.6449.Anborgh P.H., Caria L.Br., Chambers A.F. et al. Role of plasma osteopontin as a biomarker in locally advanced breast cancer. Am J Transl Res 2015;7(4):723–32.Hao C., Cui Y., Owen S. et al. Human osteopontin: Potential clinical applications in cancer (Review). Int J Mol Med 2017;39(6): 1327–37. DOI: 10.3892/ijmm.2017.2964.Xu Y.-Y., Zhang Y.-Y., Lu W.-F. et al. Prognostic value of osteopontin expression in breast cancer: a meta-analysis. Mol Clin Oncol 2015;3(2):357–62. DOI: 10.3892/mco.2014.480.Bramwell V.H., Tuck A.B., Chapman J.- A.W. et al. Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial. Breast Cancer Res 2014;16(1):R8. DOI: 10.1186/bcr3600.Karlikova M., Topolcan O., Narsanska A. et al. Circulating growth and angiogenic factors and lymph node status in earlystage breast cancer – a pilot study. Anticancer Res 2016;36(8):4209–14.Gu M., Zheng X. Osteopontin and vasculogenic mimicry formation are associated with response to neoadjuvant chemotherapy in advanced breast cancer. Onco Targets Ther 2017;10:4121–7. DOI: 10.2147/OTT.S12941.Zduniak K., Agrawal A., Agrawal S. et al. Osteopontin splice variants are differential predictors of breast cancer treatment responses. BMC Cancer 201611;16:441. DOI: 10.1186/s12885-016-2484-x.Anborgh P.H., Lee D.J., Stam P.F. et al. Role of osteopontin as a predictive biomarker for anti-EGFR therapy in triple-negative breast cancer. Expert Opin Ther Targets 2018;22(8):727–34. DOI: 10.1080/14728222.2018.1502272.